Journalist

Lee Hyo-jeong
  • Samsung Biologics Q1 revenue tops 1.2 trillion won; operating profit 580.8 billion won
    Samsung Biologics Q1 revenue tops 1.2 trillion won; operating profit 580.8 billion won Samsung Biologics said it extended its growth streak in the first quarter, starting the year strongly as it targets annual revenue of 5 trillion won.  The company reported first-quarter revenue of 1.2571 trillion won and operating profit of 580.8 billion won, it said in a regulatory filing on the 22nd. Revenue rose 25.8% from a year earlier and operating profit increased 35%. Samsung Biologics maintained its full-year revenue growth guidance of 15% to 20%, citing full utilization at Plants 1 through 4 and a ramp-up at Plant 5. The outlook, first presented in January, does not include any revenue contribution from its acquisition of a manufacturing site in Rockville, Maryland. The company said it plans to provide updated guidance reflecting that deal later. As of the end of the first quarter of 2026, Samsung Biologics reported assets of 11.9950 trillion won, equity of 7.9228 trillion won and liabilities of 4.0722 trillion won. It said its balance sheet remained stable, with a debt-to-equity ratio of 51.4% and a borrowing ratio of 11.6%. The company also reported steady order activity across contract manufacturing (CMO) and contract development (CDO). Cumulative orders since its founding totaled 112 CMO deals and 169 CDO deals, with cumulative contract value reaching $21.4 billion, it said. Samsung Biologics said it is expanding global production capacity. It completed the acquisition of the Rockville facility at the end of March, securing local staff and infrastructure and building a continuous production system. It said it is also strengthening order competitiveness through closer coordination with global drugmakers. The company said it has enhanced its service portfolio by bringing master cell bank production and vector construction in-house, enabling an end-to-end service that can move from vector build to an IND submission within nine months. It also said it secured flexible production capacity through the CEPI network to improve its ability to respond to global public health crises. Despite the strong results, labor risk was cited as a potential burden. The Samsung Biologics Mutual Growth Labor Union held a rally on the 22nd and stepped up pressure in wage and collective bargaining talks. Labor and management have held 13 rounds of negotiations since December but have not reached an agreement. The union said it plans a large-scale strike on May 1 if differences are not narrowed. Market participants have raised concerns that a strike could disrupt production and increase earnings volatility. Samsung Biologics posted 2025 revenue of 4.5570 trillion won, up 30.3% from a year earlier, and has set a 2026 revenue target of 5.3200 trillion won. A bio industry official said, "If the union goes ahead with a strike, disruptions to the May production schedule are unavoidable," adding, "We cannot rule out penalties for contract violations with global clients and potential damage to trust."* This article has been translated by AI. 2026-04-22 16:30:20
  • Pharos iBio Presents Next-Gen Cancer Drug Data at AACR, Targets Global Market
    Pharos iBio Presents Next-Gen Cancer Drug Data at AACR, Targets Global Market AI-driven drug developer Pharos iBio disclosed new research on next-generation cancer candidates at the American Association for Cancer Research meeting in San Diego, the company said. It said the presentations focused on overcoming drug resistance and expanding combination-therapy strategies, a major trend in global drug development. Pharos iBio said it presented three posters on April 20 (local time) at AACR, highlighting results from its core pipeline programs. The company released combination-study findings for PHI-101, also known as “lasmotinib,” an FLT3 inhibitor in development. The study used five approved or investigational menin inhibitors, including Johnson & Johnson’s “bleximenib” and Syndax’s “revumenib.” Pharos iBio said lasmotinib showed anti-cancer synergy when given in combination. When combined with bleximenib, tumor growth inhibition (TGI) remained at 82% to 89% two weeks after dosing was stopped, it said. The company also introduced PHI-601, a next-generation menin inhibitor, as a new strategy for treating acute myeloid leukemia. PHI-601 is being developed to reduce the menin protein itself through a targeted protein degradation (TPD)-based mechanism, it said. In preclinical research on PHI-501, a BRAF inhibitor, the company said anti-cancer effects improved when combined with immune checkpoint inhibitors. It said it observed potential for the candidate as a combination asset by modulating immune responses. Nam Gi-yeop, head of new drug development at Pharos iBio, said the company would “strengthen competitiveness as a combination-strategy partner in the global oncology market” based on its differentiated R&D capabilities.* This article has been translated by AI. 2026-04-22 11:15:17
  • Samsung Biologics Faces Strike Threat as Court Ruling Looms
    Samsung Biologics Faces Strike Threat as Court Ruling Looms Labor tensions at Samsung Biologics are edging closer to a strike after management and the union failed to reach a deal following 13 rounds of wage and collective bargaining talks since last December. With global competition intensifying, industry officials warn a walkout could disrupt production and damage confidence in South Korea’s biotech sector. Industry sources said Tuesday that the Samsung Biologics Sangsaeng Union plans to hold a rally of about 2,000 workers Wednesday at the company’s headquarters in Songdo, Incheon, and begin an all-out strike on May 1. The two sides have been unable to narrow differences over pay raises, the company’s excess-profit incentive (OPI) and the size of encouragement payments. The union has argued compensation should reflect Samsung Biologics’ operating profit of about 2 trillion won last year. It has recently stepped up pressure after securing majority status as a local chapter under Samsung Electronics’ umbrella union, according to the report. Samsung Biologics has asked the Incheon District Court to issue an injunction barring union industrial action. A court decision, expected as early as this week, is seen as a key turning point for whether the strike proceeds as planned. The company cited Article 38 of the Trade Union and Labor Relations Adjustment Act, which restricts actions that obstruct normal operations or halt work needed to protect facilities during labor disputes. The company argues that if skilled workers leave production lines, the stability of its contract manufacturing processes for biopharmaceuticals could be undermined. It has said a production stoppage could result in losses of 640 billion won a day and harm global trust. The union has maintained a hard line. Union leader Park Jae-seong said he expects the court to dismiss the injunction request because the company is making what he called excessive claims. Still, he said even if the ruling favors management, the request does not seek a total ban on all labor action, and the May 1 strike would continue within what is allowed, with possible changes in participation depending on the decision. Park also said the union is planning a second round of action, even if it means going unpaid. The union has also voiced dissatisfaction with follow-up measures after a personnel information leak in November last year. It is demanding that limits on access to personal data be written into work rules and that personnel action be taken against those suspected of union-busting, the report said. Concerns are growing that a strike could weaken the company’s competitiveness and disrupt drug supplies. The medicines Samsung Biologics produces are mainly cancer treatments or therapies for rare diseases that require ongoing dosing, raising fears that supply problems could pose risks directly affecting patients’ lives. Because Samsung Biologics’ business is based on contract development and manufacturing for global drugmakers rather than its own new drugs, a prolonged dispute could also hurt its credibility, industry officials said. Biopharmaceutical production involves cultivating and purifying living cells and requires continuous operation; even a single disruption could force the disposal of batches that took months to produce. A prolonged strike risk could extend beyond the company and erode global trust in the broader “K-bio” brand, the report said. A biotech industry official said that if a strike leads to a production halt, the company’s competitiveness in global contract bids would likely take a serious hit. 2026-04-21 18:17:56
  • Samsung Bioepis Unveils Preclinical Data on First New Cancer Drug Candidate at AACR 2026
    Samsung Bioepis Unveils Preclinical Data on First New Cancer Drug Candidate at AACR 2026 Samsung Bioepis said it has disclosed preclinical data for SBE303, a next-generation antibody-drug conjugate (ADC) cancer drug candidate, for the first time at the American Association for Cancer Research’s AACR 2026 annual meeting, as it moves beyond biosimilars to accelerate development of its own new medicines. The company said the data were presented at the meeting in San Diego, held April 17-22 (local time). SBE303 is a next-generation ADC designed to target nectin-4, a protein overexpressed in tumor cells. Samsung Bioepis said it is its first new-drug pipeline developed through joint research and licensing agreements under an open-innovation strategy with domestic and overseas partners Intocell (South Korea) and Frontline (China). According to preclinical results presented in an on-site poster session on April 20 (local time), SBE303 showed improved tumor-cell binding specificity and more efficient intracellular drug delivery compared with existing nectin-4-targeted therapies, the company said. In safety assessments, Samsung Bioepis said SBE303 produced improved results in tests for skin toxicity, a common adverse reaction associated with nectin-4-targeted therapies. It also said no interstitial lung disease (ILD), a serious side effect that can cause irreversible damage, was observed. The company said the highest non-severely toxic dose (HNSTD) was 40 mg/kg, adding that the finding supports the potential for clinical use by securing a wide therapeutic safety margin. Samsung Bioepis said it has begun global Phase 1 clinical trials of SBE303 in the United States and South Korea. It said it plans to evaluate drug safety and early efficacy in 149 patients with advanced refractory solid tumors from March this year through July 2030. 2026-04-21 11:42:20
  • Samsung Biologics Makes Debut at AACR, Targeting Early-Stage Oncology Clients
    Samsung Biologics Makes Debut at AACR, Targeting Early-Stage Oncology Clients Samsung Biologics is taking part for the first time in the American Association for Cancer Research (AACR), one of the world’s largest cancer conferences. With AACR focused on preclinical and early clinical-stage research, the company aims to promote its contract research, development and manufacturing (CRDMO) capabilities and win clients in the early phases of drug development. According to the industry on April 20, AACR is considered one of the world’s three major cancer meetings, along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). This year’s event is expected to draw more than 22,000 cancer researchers and pharmaceutical and biotech industry participants from about 140 countries. The meeting runs April 17-22 (local time) at the San Diego Convention Center in California. Samsung Biologics said it is seeking to secure early-stage customers by starting collaboration when demand is high for contract research (CRO) and contract development (CDO), then carrying projects through to commercial production — an approach it described as an “early lock-in” strategy. Jung Hyung-nam, vice president and head of Samsung Biologics’ Bio Research Center, said the company will “provide CRO and CDO services from the early development stage of innovative new drugs and establish ourselves as a trusted partner in drug development.” At AACR, Samsung Biologics has prepared a promotional booth as well as oral and poster presentations. On April 21, Alexis Santana, organoid sales director, will present on “Samsung Organoid: Enhancing Clinical Relevance in Anticancer Drug Development,” outlining how organoid services with high patient similarity could improve the success rate of drug development. The company will also present posters featuring data showing that Samsung Organoid reproduces patients’ genetic characteristics and drug responses and demonstrates a high correlation with clinical outcomes, along with a separate poster on the therapeutic and manufacturing efficiency of its bispecific antibody platform, S-DUAL.* This article has been translated by AI. 2026-04-20 17:49:34
  • Korean Drugmakers Head to AACR 2026 to Showcase Next-Gen Cancer Research
    Korean Drugmakers Head to AACR 2026 to Showcase Next-Gen Cancer Research Hanmi Pharmaceutical, Yuhan, Samsung Bioepis and Celltrion, among South Korea’s major drug and biotech companies, are heading to San Diego ahead of the American Association for Cancer Research’s AACR 2026 meeting. The companies plan to present early-stage findings on next-generation cancer drug candidates, highlight emerging trends and seek future technology-licensing opportunities. Industry officials said on April 17 that AACR, which runs through April 22 (local time), is considered one of the world’s three major cancer meetings, along with the American Society of Clinical Oncology and the European Society for Medical Oncology. AACR is known as a venue where preclinical and early clinical results are concentrated, and is widely viewed as a stage for gauging potential blockbuster candidates and licensing prospects. This year’s meeting is expected to spotlight next-generation modalities including antibody-drug conjugates, CAR-T therapies, radiopharmaceuticals and RNA-based treatments. Hanmi Pharmaceutical will present nine preclinical studies, the most among Korean companies. Its lineup spans targeted therapies and newer approaches, including an EZH1/2 dual inhibitor combined with a DNA damage inducer, a p53 mRNA cancer therapy, a 4-1BB x PD-L1 bispecific antibody and a B7H3 x PD-L1 bispecific ADC. The market expects Hanmi to extend its record of leading Korean firms in the number of presentations for four consecutive years, underscoring its research and development strength. Yuhan will also take the AACR stage, presenting research aimed at broadening the intersection of targeted cancer therapy and immuno-oncology. The move is seen as part of an effort to expand global partnerships, as AACR can serve as a starting point for licensing talks and co-development discussions. Samsung Bioepis will present preclinical data on SBE303, an ADC candidate and the company’s first new-drug pipeline, positioning it as an independent drug developer on the global stage. The company recently received U.S. Food and Drug Administration approval for an investigational new drug application for a Phase 1 clinical trial of a nectin-4-targeting ADC. Celltrion Pharm will introduce two new candidates using its dual-payload ADC platform, AD2C. The design aims to reduce dose-limiting toxicity while improving efficacy, as the company seeks differentiation in the next-generation oncology market. Biotechs scheduled for oral presentations are also drawing attention. Verismo Therapeutics, a subsidiary of the HLB Group, will present interim Phase 1 results for SynKIR-110, a CAR-T candidate for solid tumors. It will also disclose preclinical results for SynKIR-310, a CAR-T candidate for blood cancers, which was reported to have recorded a 100% survival rate, the only one to do so among comparator groups. Rznomics will give an oral presentation of interim clinical results for RZ-001, a gene therapy for liver cancer. The approach targets telomerase mRNA to induce both cancer cell death and immune cell infiltration, and is expected to draw interest because it will be the first disclosure of proof-of-concept data for the company’s RNA editing and replacement technology. A representative of a Korean pharmaceutical company said the meeting is a chance to show how competitive Korea’s oncology platforms are on the international stage. “Preclinical and early clinical stages carry high risk, but if successful, they can lead to technology exports and a reassessment of corporate value,” the person said. 2026-04-17 19:03:00
  • Hanmi Launches Task Force to Commercialize Obesity Drug Efpeglenatide; Other Pharma-Bio Updates
    Hanmi Launches Task Force to Commercialize Obesity Drug Efpeglenatide; Other Pharma-Bio Updates Hanmi launches companywide task force to commercialize obesity drug efpeglenatide this year "The development of Efe reflects Hanmi’s spirit of not being discouraged by failure and turning it into a bigger opportunity." Lim Ju-hyeon, vice chair of Hanmi Group, made the remarks April 13 at Hanmi C&C Square in Seoul as the company launched a cross-company consultative body, dubbed the “Efe Project–Seosa,” aimed at commercializing the obesity drug candidate efpeglenatide, known as Efe, within the year. The event included Lim and Hwang Sang-yeon, Hanmi Pharmaceutical’s new CEO and the company’s first chief executive hired from outside since its founding, along with key executives from new product development, marketing and R&D, the company said. The group plans to hold formal meetings monthly to align execution strategies across development, clinical work, marketing, production and distribution. Lim said Efe’s Phase 3 cardiovascular outcomes trial showed results indicating a reduced risk of major adverse cardiovascular events. She said the drug has strong protective effects for cardiovascular and kidney disease compared with other drugs in the same class currently on the market. Hwang said the company must now shift to detailed commercial preparation. “It feels like a torchbearer has just entered the main Olympic stadium,” he said, adding that Hanmi should create results “beyond sales.” He said he is confident the drug can be developed into a “premium, Korea-style obesity treatment” and pledged to grow Efe into a new engine of innovation-led growth. Daewoong Pharmaceutical wins Indonesian approval for GERD drug Fexuclu Daewoong Pharmaceutical said its self-developed gastroesophageal reflux disease treatment Fexuclu has received marketing authorization in Indonesia, as the company expands its push into Southeast Asia. The drug has now been approved in 16 countries, including South Korea, Indonesia, China, Mexico and India, and has been launched in six countries, the company said. Daewoong said April 17 that Fexuclu 40 mg, whose active ingredient is fexuprazan, was approved in Indonesia for the treatment of erosive GERD. The company also said it applied to South Korea’s Ministry of Food and Drug Safety on April 10 for an investigational new drug plan for a multinational Phase 3 trial jointly conducted in South Korea and Indonesia, seeking to expand the drug’s indication to treat gastric ulcers. Indonesia, with a population of 280 million, is the world’s fourth-most populous country and Southeast Asia’s largest economy, the company noted. A company official said a China launch is also approaching and that the Indonesian approval is expected to accelerate Fexuclu’s global expansion. Daewoong CEO Park Sung-soo said the approval in Indonesia, a key market in Southeast Asia, would be an important turning point for the company’s global push. GC Biopharma USA to present IVIG quality and safety data at U.S. conference GC Green Cross said its U.S. subsidiary, GC Biopharma USA, will present research evaluating the quality and safety of intravenous immunoglobulin products at an international conference in Denver, Colorado, running April 18-22 local time. The company said the study compared protein size and particle forms in commercially available IVIG products to assess the degree of aggregation. IVIG is widely used to treat immune disorders, and as use has increased, the importance of quality and safety has grown, it said. Protein aggregation can affect drug safety and adverse reactions during administration, making control of aggregation during manufacturing a key quality factor, the company said. The study compared five products, including GC Green Cross’ ALYGLO. The analysis found ALYGLO had lower levels of excessively aggregated proteins (multimers) and damaged protein fragments than competing products, while maintaining relatively higher levels of monomers and dimers, which are considered normal functional structures, the company said. A GC Green Cross official said the company will continue working to provide safer, more reliable treatment options for patients. Lunit to supply integrated breast cancer AI diagnostics to Lexington Clinic in the U.S. Medical AI company Lunit said it has supplied an integrated breast cancer AI diagnostic solution to Lexington Clinic in the United States, as it accelerates expansion in the Americas and aims to broaden its presence in the global breast screening market. Lunit said April 17 that Lexington Clinic adopted its mammography AI image analysis software, Lunit INSIGHT MMG, and its 3D mammography AI solution, Lunit INSIGHT DBT, to build an AI-based breast cancer diagnostic system. The clinic also introduced solutions from Lunit International, formerly Volpara, covering image quality optimization, breast density assessment and patient follow-up management. That will allow the full breast cancer diagnostic workflow to be operated on Lunit’s platform, the company said. Lunit said the deal means that about a year after integrating Lunit and Lunit International products, it has supplied the combined solution to more than 330 medical institutions across the Americas, supporting about 1 million mammography screenings annually. CEO Seo Beom-seok said supplying an end-to-end integrated solution to a large U.S. medical group and expanding to more than 330 sites reflects the combination of Lunit’s AI technology and Lunit International’s market capabilities. He said the company will continue to expand its influence beyond the Americas into the global breast cancer screening market.* This article has been translated by AI. 2026-04-17 14:51:00
  • Lotte Biologics to Present SoluFlex Link ADC Platform Data at AACR 2026
    Lotte Biologics to Present SoluFlex Link ADC Platform Data at AACR 2026 Lotte Biologics said Tuesday it will present research results on its antibody-drug conjugate, or ADC, platform technology, SoluFlex Link, at the American Association for Cancer Research meeting, AACR 2026, to be held April 17-22 in San Diego. At the conference, the company will disclose results from an evaluation of the structural stability of an ADC using SoluFlex Link technology co-developed with Kanaph Therapeutics. According to Lotte Biologics, an analysis of aggregate changes over time found that a control group without the SoluFlex linker showed increasing aggregation as time passed, while the group using the SoluFlex linker showed markedly suppressed aggregation and maintained high stability. The company said the technology could help keep product quality stable during distribution and storage. In cell tests targeting multiple markers, including epidermal growth factor receptor (EGFR) and trophoblast cell surface antigen 2 (TROP-2), the SoluFlex Link group showed stronger anticancer effects at lower concentrations than the non-applied group, the company said. It also showed strong efficacy in triple-negative breast cancer cells. Lotte Biologics said animal studies showed improved in vivo pharmacokinetics, or PK, based on high stability. The company said the findings support SoluFlex Link as a platform technology not limited to a specific antibody, with potential to improve anticancer efficacy and pharmacokinetic properties. A Lotte Biologics official said SoluFlex Link is a differentiated platform that goes beyond the limits of existing technologies, adding that the company will provide solutions to help partners and customers develop next-generation ADCs. AACR is considered one of the world’s three major cancer meetings, along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). It brings together cancer researchers and industry representatives to discuss cancer treatments and new drug development. * This article has been translated by AI. 2026-04-15 10:45:00
  • Korean Drugmakers Reshape R&D as Price Cuts and Commercial Law Changes Loom
    Korean Drugmakers Reshape R&D as Price Cuts and Commercial Law Changes Loom Korean drugmakers are reorganizing research and development around their headquarters and speeding up outside hiring and internal reshuffles as policy changes such as drug price cuts and revisions to the Commercial Act take shape. The moves are aimed at concentrating new-drug development and commercialization capabilities as profitability is expected to come under pressure. According to the industry on the 14th, Ildong Pharmaceutical decided the previous day to merge its R&D subsidiary Unovia into the parent company. Ildong cited a changing business environment and rising uncertainty, the need to strengthen competitiveness and the goal of operational stability. The company said it will integrate R&D functions into headquarters to improve management efficiency in line with institutional changes, including implementation of a revamped drug-pricing system. Unovia has led development of Ildong Pharmaceutical’s key pipeline. It has secured Phase 1 topline data for a GLP-1RA obesity drug candidate, and its P-CAB peptic ulcer treatment fadoprazan is in Phase 3 trials. Ildong said the reintegration will help speed technology licensing deals and commercialization. Industry officials view the decision as more than routine restructuring, describing it as a strategic response to pricing pressure and a broader push to overhaul corporate governance. The government is pursuing a plan to lower the pricing formula for generic drugs from 53.55% to about 45%, increasing downside pressure on earnings. At the same time, revisions to the Commercial Act are expected to add burdens related to treasury shares and governance responses. Across the pharmaceutical and biotech sector, companies are moving quickly on steps such as disposing of treasury shares, revising articles of incorporation and expanding independent directors. The revised Commercial Act includes a principle of mandatory cancellation of treasury shares, stronger board independence and changes to the structure for appointing audit committee members, affecting management strategies across the industry. Recruitment of outside specialists is also increasing. Ildong Pharmaceutical this month appointed Dr. Park Jae-hong as its new head of the R&D division. The company said Park will oversee Ildong’s overall R&D, including new-drug research and development, and that the hire will strengthen pipeline competitiveness and further raise R&D capabilities. SK Bioscience also hired Ma Sang-ho, a vice president and an infectious-disease research project management specialist, as head of the Research Support Office within its Bio Research Division. The company said it plans to strengthen R&D project management and open innovation, and to build a support system covering the full cycle from research planning to regulatory responses and operation of nonclinical and clinical sample analysis (GCLP). Yuyu Pharma hired Ryu Hyun-gi as head of its Development Division. Ryu has experience in development planning and business development after working at Kwangdong Pharmaceutical, Kyungnam Pharmaceutical, Korea Pharmbio and Hanwha Pharmaceutical. Yuyu said it aims to accelerate development of next-generation improved drugs and specialized formulations through the hire. The market expects the trend to continue for the time being. “Reorganizations centered on talent that understands clinical trials, regulatory approvals and business development are now in full swing,” a pharmaceutical company official said. “For companies seeking a breakthrough through R&D investment and securing specialized talent, it could instead become an opportunity to reset strategy.” Meanwhile, R&D spending in South Korea’s biohealth industry has continued to rise. According to the Korea Health Industry Development Institute’s “2025 Biohealth Industry Statistical Yearbook,” corporate R&D spending in the domestic biohealth industry increased from 3.4293 trillion won in 2020 to 4.4743 trillion won in 2024. * This article has been translated by AI. 2026-04-14 19:03:00
  • Centrum Cites Long-Term Research on Brain Health and Healthy Aging, Expands Korea Strategy
    Centrum Cites Long-Term Research on Brain Health and Healthy Aging, Expands Korea Strategy “Multivitamins have been shown to have positive effects beyond addressing nutrient gaps, including supporting brain health and slowing aging,” Haleon’s multivitamin brand Centrum said as it shared research accumulated over the past 35 years and outlined plans to expand Korea-specific strategies. Park Min-seok, head of medical and academic affairs at Haleon Korea, said at the “Centrum Day” event held April 14 in Seoul’s Myeong-dong that multivitamin research is moving beyond deficiency prevention toward improving quality of life and extending healthy life expectancy. “Multivitamin research is evolving from simply correcting deficiencies to improving quality of life and extending healthy life expectancy,” Park said. “Based on our global research capabilities, we will continue to expand optimal nutrition solutions for Koreans.” Organizers said Centrum, described as one of the world’s most-studied multivitamin brands, has scientific evidence supported by large-scale human studies and long-term follow-up data. Centrum said its research dates to 1985, beginning with studies of micronutrient deficiencies in China’s Linxian region, and includes long-term tracking of cancer incidence among U.S. male physicians in collaboration with the U.S. National Institutes of Health. Park said the field is also expanding to broader social value, including improved energy levels, better quality of life and reduced social costs. He added that recent work is increasingly focused on “precision nutrition” and “healthy life expectancy,” incorporating indicators such as brain health, aging biomarkers and individual lifestyle factors. Centrum also highlighted recent international findings. In an observational study of 614 adults in India last year, participants reported about a 44% improvement in energy levels after taking multivitamins, and the frequency of sick days fell by about 50%. In a health-economics model study involving older adults in Taiwan, researchers suggested that if multivitamin use slows cognitive decline, dementia cases could fall over the next 10 years, with potential social cost savings of about 65 trillion won. A Singapore study released early this year analyzed blood plasma from 662 middle-aged women and found low folate levels were linked to higher perceived stress, while B vitamins and vitamin D levels were associated with metabolic regulation. In South Korea, the company said it will strengthen a tailored approach reflecting Koreans’ dietary patterns and nutritional status. Centrum said it has continued developing localized products through research aligned with Korean eating habits and dietary reference intakes, and that this research helped lead to products such as “Centrum One Day Pack.” A Centrum official said the company will continue expanding Korea-specific data and solutions based on its global research capabilities. 2026-04-14 15:48:00